TF and Thromboembolism: Nonetheless, cases of thromboembolic events (e.g. compromised hemocompatibility, micro-and macro-thrombosis, and thromboembolism) in response to highly procoagulant TF/CD142 expressing MSC products in conjunction with suboptimal application routines have been reported in the past and call for increased caution when employing AT- and UC-derived MSCs products with high TF/CD142 expression (48, 85–89).